The state of Connecticut currently has 17 active clinical trials seeking participants for Migraine research studies. These trials are conducted in various cities, including New Haven, Hartford, Farmington and Stamford.
PArtial REbreathing for Migraine With Aura 1
NCT05546385
Recruiting
A prospective, multi-centre, randomized, double-blind, sham-controlled, parallel-group, group-sequential study to investigate safety and effectiveness of the Rehaler partial rebreathing device, in adults suffering from migraine with aura
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Migraine With Aura
Register for Updates
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396574
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/16/2024
Locations: Yale University School of Medicine, New Haven, Connecticut +1 locations
Conditions: Migraine
Register for Updates
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172
Recruiting
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/16/2024
Locations: Ki Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut
Conditions: Migraine
Register for Updates
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396236
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/15/2024
Locations: Yale University School of Medicine, New Haven, Connecticut +1 locations
Conditions: Migraine
Register for Updates
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
NCT05518123
Recruiting
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Ki Health Partners LLC, dba New England Institute for Clinical Research, Stamford, Connecticut
Conditions: Migraine
Register for Updates
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
NCT03832998
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study hypothesis is that in pediatric participants with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/10/2024
Locations: New England Institute for Clinical Research, Stamford, Connecticut
Conditions: Migraine
Register for Updates
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
NCT03836040
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/10/2024
Locations: New England Institute for Clinical Research, Stamford, Connecticut
Conditions: Migraine
Register for Updates
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/10/2024
Locations: CT Clinical Research, Cromwell, Connecticut +2 locations
Conditions: Pediatric Migraine
Register for Updates
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of age).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/10/2024
Locations: CT Clinical Research, Cromwell, Connecticut +2 locations
Conditions: Acute Treatment of Migraine
Register for Updates
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675
Recruiting
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
04/09/2024
Locations: Ki Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut
Conditions: Chronic Migraine in Children
Register for Updates
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400
Recruiting
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: Ki Health Partners LLC, dba New England Institute for Clinical Research, Stamford, Connecticut
Conditions: Migraine
Register for Updates
An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention
NCT06154070
Recruiting
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs(monthly migraine days)/month) requiring preventive treatment. Enrolled patients will receive DAXXIFY (DAX/Doxibutlinumtoxin A)administered subcutaneously per the EEG paradigm (injection pattern). The safety and efficacy outcome measures will be assessed at selected dosing segments during the 24-week treatment phase as well as the Post Treatment (4 weeks). There are 2 sites in the U.S. participating, where... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/04/2024
Locations: New England Institute For Clinical Research, Stamford, Connecticut
Conditions: Migraine Disorders
Register for Updates